Introduction
Staphylococcus aureus is a Gram-positive bacteria. S. aureus infection is one of the most common causes of skin infections in the US. These infections can be serious when they occur on surgical wounds, in the bloodstream, or in the lungs. Each year, there are more than 11 million outpatient/emergency room visits and 464,000 hospital admissions in the US due to S. aureus infections.
1 S. aureus infections are complicated, as the bacterial strains have become increasingly resistant to many commonly used antibiotics. For example, a methicillin-resistant S. aureus infection is difficult to treat, as it is resistant to a large group of antibiotics (beta-lactams) including oxacillin, penicillin, and amoxicillin. S. aureus often infects patients at hospitals due to the patients' already weakened immune systems and procedures they undergo such as surgeries and introduction of catheters, dialysis tubes, or endotracheal tubes. For example, during insertion of an orthopedic implant, bacteria (among them, S. aureus is key) from the patient's own skin and/or mucosa enters the wound site. Bacterial infection of implants is one of the leading causes of implant failure.
Even more troublesome, bacteria can easily form biofilms when they attach to a surface. A bacterial biofilm is an aggregate of one or more types of bacteria in a hydrated polymeric matrix. 2 Biofilms are a common cause of persistent infections as they are easy to form but hard to treat. S. aureus biofilms have been found on a wide range of medical devices including prosthetic heart valves, central venous catheters, urinary catheters, orthopedic prostheses, penile prostheses, contact lenses, endocarditis, otitis media, osteomyelitis, and sinusitis. 3 Once formed, S. aureus biofilms are even more difficult to treat due to the polymeric exopolysaccharide matrix they synthesize. This polymeric matrix works as a shield to prevent drugs from penetrating inside the biofilm. Therefore, it is desirable to develop active molecules that kill S. aureus at very early stages of infection, thereby preventing the formation of hard-to-treat biofilms. Along these lines, selenium has been investigated for various medical applications such as anticancer applications. Selenium as a dietary supplement has been demonstrated to reduce the risks of various types of cancers including prostate cancer, 4,5 lung cancer, 6 and esophageal and gastric-cardiac cancers.
7 Selenium-enriched probiotics have been shown to strongly inhibit the growth of pathogenic Escherichia coli in vivo and in vitro. 8 It was shown in that study that seleniumenriched probiotics (at a concentration of 0.509 µg selenium per gram of probiotics) inhibited the growth of E. coli after 96 hours in vitro. In vivo, mice were fed with and without selenium-enriched probiotics for 28 days and then inoculated with E. coli; mortality of the treated group was the lowest. 8 A series of organoselenium compounds (such as 2,4,6-tri-paramethoxyphenylselenopyrylium chloride, 9-para-chloropheny loctahydroselenoxanthene, and perhydroselenoxanthene) have been synthesized and shown to have antibacterial activities in vitro, especially against S. aureus. [9] [10] [11] However, the effects of elemental selenium nanoparticles on microorganisms remain largely unknown.
Nanotechnology has enabled researchers to synthesize nanosized particles (that is, particles that have sizes less than 100 nm in at least one dimension), using them in a wide range of applications. Nanoparticles possess increased surface areas and therefore have increased interactions with biological targets (such as bacteria) compared with conventional, micronparticles. In addition, nanoparticles are much more likely to enter cells than micron particles. As a result, nanoantibacterial particles will likely exert stronger effects on bacteria than their micro-counterparts. Therefore, the objective of this study was to examine the growth of S. aureus in the presence of selenium nanoparticles. In doing so, this study revealed a new type of antibacterial selenium nanoparticle capable of decreasing S. aureus growth.
Materials and methods synthesis of selenium nanoparticles
Selenium nanoparticles were synthesized by the reduction of sodium selenite (Alfa Aesar, Ward Hill, MA) by glutathione (reduced form, GSH) (TCI America, Portland, OR) and stabilized by bovine serum albumin (BSA) (Sigma-Aldrich, St Louis, MO). Specifically, 3 mL of 25 mM Na 2 SeO 3 , 3 mL of 100 mM GSH, and 0.15 g BSA were added to 9 mL of double distilled water in a sterile cabinet. All solutions were made in a sterile environment by using a sterile cabinet and double distilled water. After mixing the reactant solution, 1 M NaOH was added to bring the pH of the solution to the alkaline regimen. Selenium nanoparticles were formed immediately following the addition of NaOH as visualized by a color change of the reactant solution from clear white to clear red. Selenium nanoparticles were then collected by centrifuging the solution at 13,000 rpm, sterilized by ultraviolet light exposure, and resuspended in sterile double distilled water five times before use in bacteria experiments.
Material characterization
The size and morphology of the selenium nanoparticles were investigated by using a transmission electron microscope (TEM). For this, the nanoparticles in deionized water were allowed to slowly dry on formvar-coated copper grids. All imaging was carried out using a Philips JOEL TEM (New York, NY) at a voltage of 80 kV.
The size distribution of selenium nanoparticles was further investigated by the dynamic light scattering (DLS) technique using a Zetasizer-Nano-S90 (Malvern Instruments, Malvern, Worcestershire, UK).
Bacteria assays

S. aureus
A bacterial cell line of biofilm-producing S. aureus was obtained in freeze-dried form from the American Type Culture Collection (catalog number 25923). The cells were propagated in 30 mg/mL of Tryptic soy broth (TSB) (MP Biomedicals, Solon, OH). Once the second passage of bacteria reached its stationary phase, the second passage was frozen in one part TSB and one part 50% glycerol (Sigma-Aldrich). All experiments were conducted from this frozen stock. One day before bacterial seeding, a sterile 10 µL loop was used to withdraw bacteria from the frozen stock and streaked onto a TSB agar plate and incubated at 37°C for 16 hours. Bacteria from a single colony were then collected using a sterile loop and inoculated in a test tube containing 3 mL of TSB overnight. The test tube was agitated in an incubator at 37°C and shaking at 250 rpm to achieve a bacteria solution at the exponential phase of growth. Bacteria concentration was assessed by measuring the optical density of the bacterial solution at 562 nm using a standard curve correlating optical densities and bacterial concentrations. A bacteria solution was prepared at a concentration of 50,000 bacteria/mL for the bacteria experiments as described in the following page.
Dovepress
selenium nanoparticles inhibit Staphylococcus aureus S. aureus experiments
Three concentrations of selenium nanoparticles were tested against S. aureus growth: 7.8, 15.5, and 31 µg/mL. Selenium nanoparticles were mixed with bacterial solutions and cultured for 3, 4, and 5 hours in an incubator (37°C, humidified, 5% CO 2 ), shaking at 250 rpm. Bacteria cultured in TSB without selenium nanoparticles in an incubator (37°C, humidified, 5% CO 2 ), shaking at 250 rpm, were used as the controls. Blank solutions were prepared by adding selenium nanoparticles into TSB without bacteria at the above particle concentrations. Blank solutions of TSB without bacteria and without selenium nanoparticles were used as the blank for controls. At the end of the prescribed time period, bacteria concentrations in the solution were determined by measuring the optical density that was then converted to bacteria concentrations using the standard curve described above. For this, 200 µL of bacteria solutions, controls, or blanks were added to the wells of a 96-well plate, and optical densities were measured at 562 nm using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA). The measured optical densities of bacterial solutions were subtracted by that of the corresponding blanks.
Live/dead assays
At the end of the prescribed time period, live/dead assays were conducted using a BacLight Bacterial Viability Kit (Invitrogen, Carlsbad, CA) following manufacturer's instructions. The fluorescence signals were measured using a SpectraMax M5 fluorescence microplate reader (Molecular Devices).
statistical analysis
Experiments were conducted in triplicate and repeated three times unless otherwise noted. Data were collected, and the significant differences were assessed with the probability associated with one-tailed Student's t-tests. Statistical analyses were performed using Microsoft Excel (Redmond, WA).
Results and discussion
Material characterization
TEM images of selenium nanoparticles showed that the particles were spherical and approximately 40-60 nm in diameter (Figure 1 ). Further investigation of the size distribution of the selenium nanoparticles by DLS revealed that most of the particles had hydrodynamic diameters of around 100 nm (Figure 2 ). The sizes observed by DLS were larger than those determined by TEM images because BSA molecules bound to the surface of the selenium nanoparticles created a layer that made the particles appear larger. 12, 13 The size-distribution profile demonstrated that the synthesis method yielded selenium nanoparticles of a narrow size range stable in water. Nanoscale sizes of the synthesized selenium nanoparticles promoted a desirable large surface area important for increasing interactions with bacteria.
Bacterial assays
When the selenium nanoparticles were mixed with the bacterial solution, the growth of bacteria was inhibited after 3 hours (compared with the control, 0 µg/mL). The inhibitory effects continued after 4 and 5 hours (Figures 3 and 4) . The growth profile of bacteria in the presence of selenium nanoparticles is presented more clearly in Figure 4 (with the control not plotted). Figure 4 clearly shows a slow, inhibited growth profile of bacteria in the presence of selenium nanoparticles. Bacterial growth was inhibited approximately 20 times (compared with controls) after 3 hours, 50 times after 4 hours, and 60 times after 5 hours (Figures 3 and 4) .
Live/dead assays were further conducted to determine the percentage of live bacteria in each bacterial solution.
Results showed that at all the concentrations of selenium nanoparticles tested and all the time points tested (ie, 3, 4, and 5 hours), the percentage of live bacteria in the solution having selenium nanoparticles was significantly smaller than that in the solution without selenium nanoparticles (ie, controls) ( Figure 5 ). More than 90% of bacteria in the control were alive, while only 60% of bacteria were alive in the selenium nanoparticle-treated experiments. No significant difference in the percentages of live cells was observed between the three tested concentrations of selenium nanoparticles. There was also no significant difference in the percentage of live cells between the tested time points within each concentration of selenium nanoparticles. These live/ dead results indicated that selenium nanoparticles actually killed the bacteria rather than inhibiting growth. The selenium nanoparticles also continuously killed the bacteria so that although the total number of bacteria increased slightly (or did not increase during the time period tested), the percentage of live cells remained unchanged (Figures 4 and 5 ).
Discussion
Nanoparticles have been increasingly studied for a wide range of medical applications. The advantages of nanoparticles include their high surface-to-volume ratios and their nanoscale sizes. The high surface areas of nanoparticles allow for more active sites for interacting with biological entities such as cells. The higher surface areas of nanoparticles compared with conventional micron-size particles also offer more sites for functionalization with other bioactive molecules, such as anticancer and antibacterial drug molecules. The nanoscale sizes of nanoparticles provide valuable properties that are not available in micron particles. For example, nanoparticles (with or without drugs attached) of sizes between 10 and 100 nm can penetrate tissues with tumors and can kill cancerous cells while not affecting healthy cells. This effect, called "enhanced permeation and retention," is attributed to the fact that the blood vessels in tissues with tumors have pore sizes ranging from 100 to 800 nm, while the vessels in healthy tissues have much smaller pore sizes, from 2 to 6 nm. 14 The same advantages can be used for inhibiting bacteria functions. Using nanoparticles to impede bacterial growth is an increasingly attractive approach to prevent and treat infections. Thanks to the advancement of nanotechnology, a wide range of nanoparticles (such as iron oxide nanoparticles, quantum dots, and gold nanoparticles) have been created.
However, few studies have reported that nanoparticles can effectively kill bacteria, in particular S. aureus. Some researchers have reported the synthesis of selenium nanoparticles and their biological effects toward mammalian cells in vitro. 15, 16 Others reported inhibitory effects of selenium compounds (in the form of coatings) on the growth of some types of bacteria. 17 However, the influence of selenium nanoparticles on bacteria growth remains largely unexplored. 
